Form 8-K - Current report:
SEC Accession No. 0001628280-22-015488
Filing Date
2022-05-26
Accepted
2022-05-26 17:05:06
Documents
13
Period of Report
2022-05-26
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K espr-20220526.htm   iXBRL 8-K 60357
2 EX-3.1 exhibit31.htm EX-3.1 6608
  Complete submission text file 0001628280-22-015488.txt   214840

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT espr-20220526.xsd EX-101.SCH 1915
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT espr-20220526_lab.xml EX-101.LAB 25850
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT espr-20220526_pre.xml EX-101.PRE 13593
7 EXTRACTED XBRL INSTANCE DOCUMENT espr-20220526_htm.xml XML 11512
Mailing Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108
Business Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108 734-887-3903
Esperion Therapeutics, Inc. (Filer) CIK: 0001434868 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35986 | Film No.: 22971189
SIC: 2834 Pharmaceutical Preparations